Patient Characteristics (n = 42)
| Characteristic | Data |
| Age (y) | |
| Median | 54 |
| Range | 23–80 |
| Sex (n) | |
| Men | 25 (60) |
| Women | 17 (40) |
| Time from diagnosis (y) | |
| Median | 5.6 |
| Range | 0.8–15.4 |
| RET mutation (n) | |
| Yes | 3 (7) |
| No | 24 (57) |
| Not done | 15 (36) |
| Calcitonin serum level (pg/mL) | |
| Median | 2,930 |
| Range | 136–83,652 |
| CEA serum level (ng/mL) | |
| Median | 58.8 |
| Range | 1.4–3,814 |
| Calcitonin DT (y) | |
| Median | 1.25 |
| Range | 0.18–29.26 |
| CEA DT (y) | |
| Median | 1.79 |
| Range | 0.42–23.76 |
| Location of disease (n) | |
| Nonparenchymal | 5 (12) |
| Parenchymal | 7 (17) |
| Both | 30 (71) |
| Bone marrow status (n) | |
| Involvement | 23 (55) |
| No involvement | 19 (45) |
| Baseline PET SUVmax* | |
| Median | 5.2 |
| Range | 2.1–16.3 |
| Risk subgroup | |
| Low (DT ≥ 2 y) | 11 (26) |
| Intermediate (DT 6 mo to 2 y) | 21 (50) |
| High (DT < 6 mo) | 9 (21) |
| Not done | 1 (2) |
| Pretargeting delay in days (n) | |
| 4 | 8 (19) |
| 5 | 31 (74) |
| 6 | 3 (7) |
| Tumor targeting (n) | |
| Grade 1 | 6 (14) |
| Grade 2 | 17 (40) |
| Grade 3 | 18 (43) |
| Not done | 1 (2) |
↵* SUVmax measured in 23 patients.
Data in parentheses are percentages.